VEGFA overexpression was previously reported to synergizes EGFR as one of the resistant mechanisms of BV therapy in other cancers,[18] therefore it could explain why EGFR mutated OC had poorer PFS compared to EGFR wlidtype OC. The gene discussed is EGFR; the disease is cancer.